2024-02-07 22:18:05 ET
Ascendis Pharma A/S (ASND)
Q4 2023 Earnings Conference Call
February 7, 2024 04:30 PM ET
Company Participants
Timothy Lee - IR
Jan Mikkelsen - President and CEO
Scott Smith - EVP and CFO
Conference Call Participants
Jessica Fye - JPMorgan
Tazeen Ahmad - Bank of America
Li Watsek - Cantor
David Lebowitz - Citi
Joseph Schwartz - Leerink Partners
Derek Archila - Wells Fargo
Kelly Shi - Jefferies
Paul Choi - Goldman Sachs
Andreas Argyrides - Wedbush
Leland Gershell - Oppenheimer
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Tim Lee, Senior Director of Investor Relations. Please go ahead.
Timothy Lee
Thank you, operator and thank you everyone for joining our full year 2023 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma.
Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President and Head of Clinical Development, Oncology; and Joe Kelly, Senior Vice President, Head of US Commercial, Endocrinology. .
Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SKYTROFA for the US and European markets. as well as certain financial expectations for 2024, our commercialization and development of YORVIPATH in the EU and expected timing of the FDA review and potential launch of TransCon PTH in the US, our pipeline candidates and our expectations with respect to their continued progress and potential commercialization, our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, our ongoing and planned regulatory filings and our expectations regarding the timing, and the results of regulatory decisions. Our ability to create value in multiple therapeutic areas outside of endocrinology rare disease, our progress towards Vision 2030, and the potential success of Eyconis.
These statements are based on information that is available to us as of today. Actual results could differ materially from those in our forward-looking statements, and you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change, except as required by law.
For additional information concerning the factors that could cause actual results to differ materially, please see our forward-looking statements section in today's press release and the risk factors section of our most recent annual report on Form 20-F filed with the SEC later today, February 7th, 2024....
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript